Multiple myeloma and I'm about to get bispecific in the next two weeks. What advanced tests should I get

Advanced Testing Before Bispecific Antibody Therapy

Great question—getting the right baseline tests before starting a bispecific antibody is important for monitoring safety and treatment response. Here's what you should discuss with your oncology team:

Key Baseline Tests to Discuss

Minimal Residual Disease (MRD) Testing:

• Flow cytometry or next-generation sequencing (NGS) of bone marrow or peripheral blood
• This establishes your baseline disease burden and helps track response to the bispecific
• According to NCCN Guidelines for Multiple Myeloma, MRD assessment is increasingly important for evaluating treatment efficacy

Comprehensive Metabolic Panel & Organ Function:

• Baseline kidney function (creatinine, eGFR) - critical since bispecifics can affect renal function
• Liver function tests
• Electrolytes and albumin
• These establish your baseline before treatment starts

Complete Blood Count (CBC):

• Baseline hemoglobin, white blood cells, and platelets
• Bispecifics can cause cytopenias (low blood cell counts), so knowing your starting point matters

Cardiac Assessment (if not recent):

• EKG or echocardiogram depending on your bispecific choice and cardiac risk factors
• Some bispecifics have cardiac considerations

Infectious Disease Screening:

• Hepatitis B, C, and HIV status (if not already documented)
• Bispecifics affect immune function, so baseline status is important

Bone Marrow Biopsy (if not very recent):

• Cytogenetics and FISH testing for high-risk features
• This helps your team understand your disease biology and predict response

Questions to Ask Your Oncologist

1. "Which bispecific am I starting, and are there specific baseline tests recommended for that particular drug?" (Different bispecifics have different monitoring needs)

2. "Do you want MRD testing at baseline so we can track response?"

3. "What's your monitoring schedule after I start—how often will we check labs and imaging?"

4. "Are there any organ function tests I should get given my specific health situation?"

5. "Should I get any cardiac or infectious disease screening before starting?"

Important Context

According to ASCO Guidelines on Multiple Myeloma, baseline assessment should include disease characterization and organ function evaluation before any new therapy. The American Cancer Society also emphasizes that bispecific antibodies (like teclistamab and talquetamab, which are FDA-approved for relapsed/refractory myeloma) require careful baseline monitoring because they work through immune activation mechanisms.

Your oncology team will have specific protocols for YOUR bispecific choice, so these questions will help ensure you're getting exactly what you need before starting.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.